Investors Buy Large Volume of Call Options on Astrazeneca (NYSE:AZN)

Astrazeneca Plc (NYSE:AZN) was the target of some unusual options trading on Thursday. Stock investors purchased 49,737 call options on the stock. This is an increase of approximately 1,415% compared to the average volume of 3,284 call options.

Analyst Ratings Changes

Several equities analysts recently issued reports on AZN shares. Weiss Ratings cut Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, July 28th. Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research report on Sunday, October 11th. Citigroup reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday, October 6th. Nordea Equity Research upgraded shares of Astrazeneca from a “sell” rating to a “buy” rating in a research report on Tuesday. Finally, Bank of America restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Fifteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Astrazeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of $206.67.

Astrazeneca Trading Down 0.9%

AZN traded down $1.45 during trading on Friday, reaching $165.23. 3,457,680 shares of the company’s stock were exchanged, compared to its average volume of 2,787,129. The company’s fifty day moving average price is $162.16 and its 200-day moving average price is $176.23. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89. Astrazeneca has a fifty-two week low of $153.41 and a fifty-two week high of $212.71. The firm has a market capitalization of $256.26 billion, a PE ratio of 24.70, a P/E/G ratio of 1.41 and a beta of 0.27.

Astrazeneca (NYSE:AZN) last issued its earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, beating the consensus estimate of $2.50 by $0.13. The company had revenue of $15.38 billion during the quarter, compared to analysts’ expectations of $15.44 billion. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. The business’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.17 EPS. As a group, equities analysts forecast that Astrazeneca will post 9.38 EPS for the current year.

Institutional Investors Weigh In On Astrazeneca

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ariston Services Group bought a new position in Astrazeneca during the 3rd quarter worth approximately $222,000. Encompass More Asset Management grew its holdings in Astrazeneca by 46.2% during the third quarter. Encompass More Asset Management now owns 2,167 shares of the company’s stock valued at $350,000 after purchasing an additional 685 shares during the period. Fulcrum Wealth Advisors LLC increased its stake in Astrazeneca by 11.1% in the third quarter. Fulcrum Wealth Advisors LLC now owns 14,712 shares of the company’s stock valued at $2,376,000 after purchasing an additional 1,467 shares in the last quarter. New England Research & Management Inc. bought a new stake in Astrazeneca in the third quarter valued at approximately $1,234,000. Finally, Vontobel Holding Ltd. bought a new stake in Astrazeneca in the third quarter valued at approximately $71,603,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca News Summary

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AI partnership expands pipeline potential: AstraZeneca agreed to collaborate with insitro on machine-learning-based drug discovery for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. The deal could be worth up to $1.5 billion, including upfront and milestone payments plus royalties, giving AstraZeneca access to new potential therapies while spreading early-stage research risk. AstraZeneca Enters AI Drug Discovery Partnership
• Positive Sentiment: Analysts remain constructive: RBC Capital Markets reiterated its “outperform” rating and 14,500-pence target, forecasting third-quarter revenue and core EPS modestly above consensus ahead of AstraZeneca’s October 30 results. Citi also raised its target to £186. RBC Keeps AstraZeneca at Outperform
• Positive Sentiment: Potentially attractive valuation: A market commentary highlighted that AZN has declined more than 8% this year even though operating performance has remained relatively resilient. The article points to a forward price-to-earnings multiple of about 14.6 times as a possible long-term buying opportunity. AstraZeneca Valuation Commentary
• Neutral Sentiment: Options activity surged: Investors purchased 49,737 call options, more than 14 times typical volume. This may signal bullish positioning, but options activity alone does not establish a fundamental change in the company’s outlook.
• Neutral Sentiment: Mixed analyst signal: Zacks Research upgraded AstraZeneca from “strong sell” to “hold,” indicating reduced pessimism but not a bullish recommendation. AZN is also being monitored for breast-cancer sales growth, expanded approvals and clinical milestones.
• Negative Sentiment: Underperformance remains an overhang: AstraZeneca continues to lag the broader market, and investors may be waiting for upcoming earnings and the AVANZAR lung-cancer trial before assigning greater value to its pipeline.

Astrazeneca Company Profile

AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, United Kingdom. Its research, development and commercial operations focus on prescription medicines for serious and chronic diseases, with an emphasis on discovering and delivering innovative therapies rather than operating as a diversified healthcare conglomerate.

The company’s principal therapeutic areas include oncology; cardiovascular, renal and metabolic diseases; respiratory and immunological conditions; and rare diseases.